EUROGENIC intermittent claudication secondary to LSS is a degenerative condition prevalent in the general population 50 years of age and older, and decompressive surgery for LSS is now the most commonly performed spinal surgery in patients age 65 years and over. 6, 8 The reported success rates of decompressive surgery vary, reflecting the poor scientific quality of the clinical literature, which consists mostly of uncontrolled, nonrandomized, single-center studies involving physicianassessed outcomes measures. The results of these studies are difficult to interpret and even more difficult to compare with those reported in other published studies.
accurate assessment of the clinical benefit of treatment by removing the possible bias of the treating physician. The ZCQ, also referred to as the Swiss Spinal Stenosis Survey, is a condition-specific questionnaire designed and validated for patients with LSS. 7, 22, 26, 27 Because of its relatively recent introduction, however, few published studies have reported results measured using the ZCQ.
The SF-36, on the other hand, has been widely used in a variety of orthopedic studies, allowing comparisons across a broad range of medical conditions and therapies. 19, 30 Well-designed, prospective clinical studies typically include both a condition-specific survey to assess the direct benefit of the treatment, as well as a general health survey to assess the overall benefits provided by the treatment. For example, using the SF-36, Hozack and colleagues 13 and McGregor and Hughes 17 have demonstrated that decompressive surgery improves the QOL in patients with LSS.
The present study was designed to compare the QOL outcomes in patients with LSS treated with a new device, the X STOP Interspinous Process Decompression System (St. Francis Medical Technologies, Inc., Driebergen, The Netherlands), with those obtained in patients who underwent nonoperative therapy. Nonoperative therapy was chosen as a control modality, both because it is a common treatment for mild to moderate neurogenic intermittent claudication and because implantation of the X STOP device, similar to nonoperative care, does not require a highly invasive procedure.
The specific aims of the current study were to 1) compare the QOL in the X STOP-treated patients with that in the nonoperatively treated patients, and 2) compare the results of both X STOP-and nonoperatively treated patients in the present study with results reported in studies of other spinal procedures in which investigators used the SF-36. We hypothesized that 1) the posttreatment SF-36 scores obtained in the X STOP-treated patients would be significantly greater than those in patients who underwent nonoperative therapy and 2) the benefits of X STOPbased therapy would be comparable to those reported in conjunction with lumbar decompression in the treatment of LSS.
Clinical Material and Methods

Patient Selection
Investigators from eight community hospitals and one teaching hospital treated 191 patients between June 2000 and July 2001. Patients were randomized either to the X STOP or nonoperative treatment groups in a prospective controlled trial. The study was conducted under a Food and Drug Administration-approved Investigational Device Exemption and was approved by the institutional review board at each participating institution prior to initiation. All patients signed an institutional review boardapproved informed consent form prior to participating in the study.
Patients were eligible for inclusion if they were 50 years of age or older, had symptoms of radiographically confirmed one-or two-level LSS, and had leg, buttock, or groin pain, with or without back pain, that could be relieved during flexion. Patients had to be able to sit for 50 minutes without pain, walk 50 feet or more, and have completed at least 6 months of nonoperative therapy. Primary exclusion criteria included a fixed motor deficit, cauda equina syndrome, significant lumbar instability, previous lumbar surgery, significant peripheral neuropathy or acute denervation secondary to radiculopathy, a scoliotic Cobb angle greater than 25˚, spondylolisthesis greater than Grade I (score range I-IV) at the affected level, presence of pathological fracture(s) or severe osteoporosis of the vertebra(e) and/or hip(s), obesity, active infection or systemic disease, Paget disease or metastasis to the vertebrae, or steroid use for more than 1 month within 12 months preceding the study.
Patients were randomized either to the X STOP or nonoperative group using block randomization by surgical center. An individual not involved in the treatment or care of the patients performed the randomization and informed the surgeon of its result. Patients randomized to the nonoperative group received an epidural steroid injection on enrollment and were eligible for additional injections as needed, as well as nonsteroidal antiinflammatory drugs, analgesic agents, and physical therapy. Physical therapy consisted of education on back care and modalities such as ice packs, heat packs, massage, stabilization exercises, and pool therapy. Braces such as abdominal binders and corsets were permitted, but body jackets and chair back braces were not.
X STOP Operative Technique
The patient was placed on a radiolucent table in the right lateral decubitus position and asked to flex his or her spine (Fig. 1) . After the operative level(s) was/were confirmed fluoroscopically, the patient received a local anesthetic; general anesthesia was not typically required. A midsagittal incision of approximately 4 cm was made over the spinous processes of the stenotic level(s), and the musculature was dissected to the level of the laminae and facet joints. Hypertrophied facet joints could be partially resected to ensure that anterior placement of the implant would be feasible. A curved dilator was inserted in the anterior margin of the interspinous space to pierce the interspinous ligament, and a sizing distractor was then inserted to determine the appropriate implant size. The X STOP ( Fig. 2 ) was secured to the insertion instrument and placed in the interspinous space. An adjustable wing was fastened to the implant and was then positioned as close to the spinous process as possible.
Outcomes Assessment
All SF-36 data were collected prior to the initial treatment and then at 6 weeks, 6 months, 1 year, and 2 years following the initial treatment. 19, 30 The SF-36 questionnaire is a validated general health outcomes measure developed to assess and compare the general health status of patients. General health outcomes measures are useful when comparing the relative burden of different diseases or the relative benefit of different treatments. The questions and domains of the SF-36 were developed to be nonspecific in terms of age, disease, or treatment group. The questionnaire is composed of eight domains of the most frequently represented health concepts, and each domain contains between two and 10 questions. Physical Functioning addresses the presence and severity of a patient's physical limitation, and the RP domain pertains to healthrelated limitations in the type or amount of work a patient can perform. Bodily Pain involves the frequency and magnitude of the pain, and the GH domain patients' assessments of their overall health. Vitality is a measure of a patient's energy level and SF is used to assess health-related effects on social activities. Role Emotional measures the impact of emotional problems on work and other daily activities, and MH includes questions from each of the four major mental health dimensions: anxiety, depression, loss of behavioral or emotional control, and psychological well-being. The physical domains such as PF, RP, and BP are often responsive to the benefits of surgery, and the mental health domains are more responsive to treatments for mental disorders. 29 The eight domains can also be combined into two aggregate domains: the PCS and the MCS. These aggregate domains provide a summary of the patient's physical and mental status.
Statistical Analysis
Using an ANOVA, individual pre-and posttreatment
FIG. 1. Sketches illustrating the X STOP surgical technique. A:
The patient is placed on the surgery table in the flexed, right lateral decubitus position, and a small incision is made over the spinous processes of the stenotic level(s). B: The musculature is dissected to the level of the facet joints and laminae, and a curved dilator is used to pierce the anterior margin of the interspinous ligament. C: An adjustable sizer is placed in the rent created by the curved dilator and is used to size the interspinous space. D: The X STOP is placed in the anterior interspinous space. E: A universal wing is attached to prevent the implant from migrating within or out of the interspinous space. mean SF-36 domain scores were compared between X STOP and nonoperative groups. Using an ANOVA, mean SF-36 domain scores were compared at each time point within a treatment group. An intent-to-treat analysis was performed at the 2-year time point for the X STOP and nonoperative groups and compared with the 2-year results reported in other studies. Statistical significance was set at a probability value less than 0.05.
Results
Demographic Data
Of 191 treated patients enrolled in this study, 100 were randomized to the X STOP group and 91 to the nonoperative group. The age, height, and weight of patients in the two groups were similar (Table 1) . Sixty-four percent of the X STOP-treated patients and 80% of the nonoperatively treated patients were treated for single-level stenosis. In the X STOP group, 89% of the patients underwent implantation of the device at the L4-5 level and 43% at L3-4; treatment of no other level exceeded 5% of the cases.
The 2-year follow-up SF-36 data were analyzed for 82 X STOP-treated patients and 53 nonoperatively treated patients; four patients in the X STOP group died of causes unrelated to the implant, in one the implant was removed without further surgery, six underwent a laminectomy, six failed to complete the questionnaire, and one withdrew from the study. In the nonoperative group, three patients died of causes unrelated to the treatment, 24 underwent a laminectomy, six failed to complete the questionnaire, and five withdrew from the study.
Comparison of X STOP and Nonoperative Results
There were no significant differences between the pretreatment SF-36 scores of either group in any domain (Tables 2 and 3) . At all posttreatment time points, the mean domain scores documented in the X STOP group were significantly greater than those in the nonoperative group, with the exception of the mean GH, RE, and MCS scores at 2 years (Tables 2 and 4 ). There was no significant difference between the intent-to-treat analysis and the 2-year data for both groups. The greatest difference was a decrease of 3.6 points and 5.5 points in SF for the X STOP and nonoperative groups, respectively.
Pretreatment Compared With Posttreatment SF-36 Scores
At all posttreatment time points, the mean domain scores of the X STOP group were significantly greater than the mean baseline scores, except the mean GH scores at 6 months, 1 year, and 2 years (Tables 2 and 5 ). At all posttreatment time points, the mean nonoperative domain scores were not significantly different from the mean baseline scores, except the mean PF score at 6 months; the mean RP scores at 6 weeks and 1 year; the mean BP scores at 6 weeks, 6 months, and 1 year; the mean GH scores at 1 year and 2 years; and the mean PCS score at 1 year (Tables 2 and 5 ).
Changes Over Time
For a given domain, there was no significant difference among the mean SF-36 scores at any follow-up interval in either the X STOP or nonoperative group (Tables 2 and 6 ).
Results of X STOP Treatment Compared With Laminectomy
Outcome data obtained during a mean follow-up duration of 12.8 months (range 2.5-26.9 months) were available for all six of the X STOP-treated patients and 22 of the control patients who underwent a laminectomy following the initial X STOP or nonoperative treatment, respectively. To compare the two surgical treatments, the pooled results from the laminectomy group (total 28 cases) were compared with the results demonstrated in X STOP-treated patients who did not undergo laminectomy. The mean preoperative SF-36 scores in the X STOP group were significantly greater that those in the laminectomy group (where preoperative scores in the laminectomy group refer to the SF-36 scores immediately preceding the laminectomy surgery) in all domains except RE (Tables 7  and 8 ). The mean postoperative SF-36 scores in the X STOP group were significantly greater that those in the laminectomy group in all domains (Tables 7 and 8 ). There was no significant difference between mean changes in the pre-to postoperative SF-36 scores of the X STOP and laminectomy groups in any domain (Tables 7 and 8 ). The mean postoperative SF-36 scores documented in the laminectomy group were significantly greater than the preoperative scores in all domains except for the GH, RE, MH, and MCS (Table 9) . [13] [14] [15] 18 knee arthritis, 3, 13, 18 shoulder disorders, 10, 11, 23 and tibial fractures. 16 An advantage of a general health outcomes measure such as the SF-36 over a conditionspecific measure is that it permits health-state comparisons not only among groups with the same disease state but also among different diseases, treatments, and patient populations.
Lumbar Spinal Stenosis
Four studies of LSS populations treated surgically contain pre-and postoperative SF-36 scores. 2, 15, 19, 27 The results of these studies, as well as those obtained in the present study, indicate that patients with LSS have similar pretreatment SF-36 scores in each domain. The patient populations reported by Strömqvist, et al., 25 and McGregor and Hughes 17 seem to have lower baseline SF-36 scores, and the populations studied by Atlas, et al., 2 seem to have somewhat higher scores; the X STOP and nonoperative population scores lie in between the extremes for most domains. As one might expect, the PF, RP, BP, and the PCS pretreatment scores for a physical disorder such as LSS are the lowest compared with other SF-36 domains. It has also been shown that these same domains exhibit the most improvement following treatment. The results demonstrate that the PH, RP, BP, and PCS domains improve the most following surgical decompression or X STOP implantation, as indicated by a change in the pretreatment domain score to the posttreatment score. The results of the subgroup comparison (laminectomy compared with X STOP implantation) suggest that the X STOP device provides relief similar to that of decompressive surgery in patients with LSS (Tables 7 and 8) .
As described by Ware and Sherbourne, 30 the PF, RP, BP, and PCS domains are valid physical health measures that often indicate changes in a patient's physical function. The MH, RE, SF, and MCS domains are valid mental health measures that are often used in studies of mental instability and depression. 29 As shown previously, the greatest domain score changes following X STOP surgery were in the realms that pertain to physical function. The mental health domains showed relatively little change, which would be expected because the implant is not intended to alter a patient's mental state. This trend is reflected in a number of surgical studies in the orthopedic literature.
13,29,30
Conclusions
The results of this study demonstrate that the X STOP device produces a general health benefit in patients with LSS that is significantly better than conservative treatment. In addition, the treatment is comparable to the benefit resulting from the surgical treatment of LSS. Although evaluation of the SF-36 results suggests that the X STOP implant is comparable to lumbar decompression, the outcomes measures do not reflect the additional benefits offered by the X STOP Interspinous Process Decompression technique. The X STOP procedure is often performed using a local anesthetic, frequently does not require removal of any osseous tissue, and produces relatively little pain compared with other more invasive techniques, and these benefits allow for a faster recovery.
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Quality of life in X STOP-treated patients 505 The beneficial results found in the present study have also been demonstrated in the condition-specific ZCQ completed by the patients. 31, 32 These results show that the X STOP provides significant clinical improvement in the symptom severity and physical function in patients with LSS compared with conservative therapy and is comparable with traditional lumbar decompression techniques. The results obtained in the present study indicate that the X STOP not only provides an almost immediate effect, but the effect is sustained for at least 2 years. 
